给予高肽量[177Lu]Lu-HA-DOTATATE后的生长抑素受体饱和:何时足够即止
该回顾性研究比较了晚期转移性神经内分泌肿瘤患者接受低、标准和高肽量[177Lu]Lu-HA-DOTATATE后SPECT/CT上的器官与肿瘤摄取。高肽量(平均346 µg)较标准肽量(平均178 µg)显著降低脾、肾和肿瘤摄取;低肽量(平均109 µg)较标准肽量(平均202 µg)增加脾摄取但降低肿瘤摄取。结论认为高肽量(约350 µg)不推荐用于标准剂量PRRT,标准肽量(约200 µg)似乎更合适。
要点
- 高肽量(平均346 µg)较标准肽量(平均178 µg)显著降低脾、肾和肿瘤的[177Lu]Lu-HA-DOTATATE摄取。
- 低肽量(平均109 µg)较标准肽量(平均202 µg)增加脾摄取,但显著降低肿瘤摄取。
- 高肽量(约350 µg)不推荐用于标准剂量PRRT,标准肽量(约200 µg)似乎更合适。
核心结论
- 这些发现证实[177Lu]Lu-HA-DOTATATE的器官和肿瘤累积呈肽量依赖性,高肽量和标准肽量下脾存在受体饱和,而肿瘤和肾受体饱和仅在高肽量下出现。
- 高肽量(约350 µg)不推荐用于标准剂量PRRT,标准肽量(约200 µg)似乎更合适以实现最佳肿瘤累积并限制器官摄取。
研究设计与样本
- 回顾性纳入接受7.4 GBq 177-镥标记低或高量HA-DOTATATE的神经内分泌肿瘤患者数据,并纳入同一患者其他含标准肽量的PRRT周期进行患者内比较。
- 高肽量组13例患者(平均346 µg,标准肽量平均178 µg),低肽量组15例患者(平均109 µg,标准肽量平均202 µg)。
- 在治疗后SPECT/CT上对脾、肝、肾、骨髓、血池和肿瘤病灶进行摄取定量,采用配对Wilcoxon符号秩检验比较每位患者相邻两周期的摄取差异。
主要发现
- 高肽量组较标准肽量组脾摄取显著降低(p = 0.00012)。
- 高肽量组较标准肽量组肾摄取显著降低(p = 0.013)。
- 高肽量组较标准肽量组肿瘤病灶摄取显著降低(p < 0.0001)。
- 低肽量组较标准肽量组脾摄取增加(p = 0.015),而肿瘤摄取显著降低(p = 0.015)。
关键数值与推荐
- 高肽量组平均346 µg vs 标准肽量平均178 µg,脾摄取显著降低(p = 0.00012)、肾摄取显著降低(p = 0.013)、肿瘤病灶摄取显著降低(p < 0.0001)。
- 低肽量组平均109 µg vs 标准肽量平均202 µg,脾摄取增加(p = 0.015),肿瘤摄取显著降低(p = 0.015)。
- 高肽量(约350 µg)不推荐用于标准剂量PRRT;标准肽量(约200 µg)似乎更合适以实现最佳肿瘤累积并限制器官摄取。
临床怎么用
- 作者认为高肽量(约350 µg)不推荐用于标准剂量PRRT。
- 作者认为标准肽量(约200 µg)似乎更合适以实现最佳肿瘤累积并限制器官摄取。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Receptor saturation during peptide receptor radionuclide therapy (PRRT) could result in altered [177Lu]Lu-HA-DOTATATE uptake in tumors and organs. Therefore, receptor expression status and effects of different (unlabeled) administered peptide amounts during PRRT need to be evaluated. The aim of this study was to assess potential receptor saturation during PRRT by comparing organ and tumor uptake after administration of [177Lu]Lu-HA-DOTATATE with low, standard and high administered peptide amounts in patients with advanced metastatic neuroendocrine tumors (NETs). METHODS: Data of NET patients that received 7.4 GBq 177-Lutetium labeled to a low or high amount of HA-DOTATATE were retrospectively included. From included patients other PRRT cycles, containing standard administered peptide amounts, were included for intra-patient comparison. Uptake quantification was performed for spleen, liver, kidney, bone marrow, blood pool and tumor lesions on post-treatment SPECT/CT scans. A paired Wilcoxon signed-rank test was performed to determine uptake differences between two adjacent cycles for each patient. RESULTS: Thirteen patients received [177Lu]Lu-HA-DOTATATE with a high administered peptide amount (mean 346 µg vs 178 µg standard peptide amount). Low peptide amounts were administered to fifteen patients (mean 109 µg vs 202 µg standard peptide amount). High administered peptide amount resulted in significantly lower [177Lu]Lu-HA-DOTATATE uptake in the spleen (p = 0.00012), kidney (p = 0.013) and tumor lesions (p < 0.0001) versus standard peptide amounts. For low administered peptide amount, uptake was increased in the spleen (p = 0.015), while tumor uptake was significantly reduced (p = 0.015) compared to uptake after administration of standard peptide amounts. CONCLUSIONS: These findings confirmed a peptide amount-dependent organ and tumor accumulation for [177Lu]Lu-HA-DOTATATE, with receptor saturation in spleen for high and standard peptide amounts, while tumor and kidney receptor saturation occur only with high administered peptide amounts. A high peptide amount (~ 350 µg) is not recommended for standard-dose PRRT and standard amounts (~ 200 µg) seem more suitable to achieve optimal tumor accumulation with limited organ uptake.
引用
- Siebinga H, Veerman CHAM, de Wit-van der Veen L, et al. Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough. EJNMMI Res. 2022. PMID: 36515683. doi:10.1186/s13550-022-00946-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。